Mostafavian Zahra, Vakilian Farveh, Torkmanzade Leila, Moghiman Toktam
Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Cardiothoracic Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Med Life. 2018 Oct-Dec;11(4):359-364. doi: 10.25122/jml-2018-0013.
Heart failure with reduced ejection fraction (HFrEF) is a debilitating disease in which Left Ventricular Ejection Fraction (LVEF) is ≤ 40%, and it involves various organs. Regarding the novelty of stem cell therapy in HF, we aimed at studying the effect of stem cell therapy on the QoL of patients with HFrEF. In a prospective study, 30 patients diagnosed with HFrEF who had undergone stem cell injection (study group) and 30 patients with HFrEF receiving guideline-directed medical therapy (control group) were recruited by convenience sampling during 2016 in Mashhad, Iran. Patients' quality of life, left ventricular ejection fraction and their disability degree were studied twice with a 3-month interval. For data analysis, paired t-test, chi2 and multivariate linear regression were used. The mean age of study and control groups was 61.3±10.24 and 60.93±7.88 years respectively. Ninety percent of the cases and 56.7% of the controls were male (P=0.003). A significant difference in QoL was observed before and after treatment in each group (P<0.05). However, the QoL score showed no statistical difference between the two groups following treatment (P=0.13). The same result was achieved for LVEF (P=0.18); whereas the NYHA function class showed a significant difference between the two groups following treatment (P=0.017). According to the results, it seems that the treatment of HFrEF patients with stem cells is as effective as conventional therapies in improving the LVEF and QoL and more efficient than conventional treatments in increasing the patients' general satisfaction with life.
射血分数降低的心力衰竭(HFrEF)是一种使人衰弱的疾病,其左心室射血分数(LVEF)≤40%,且累及多个器官。关于干细胞疗法在心力衰竭治疗中的创新性,我们旨在研究干细胞疗法对HFrEF患者生活质量(QoL)的影响。在一项前瞻性研究中,2016年于伊朗马什哈德通过便利抽样招募了30例诊断为HFrEF且接受过干细胞注射的患者(研究组)和30例接受指南指导药物治疗的HFrEF患者(对照组)。患者的生活质量、左心室射血分数及其残疾程度每隔3个月进行两次研究。数据分析采用配对t检验、卡方检验和多元线性回归。研究组和对照组的平均年龄分别为61.3±10.24岁和60.93±7.88岁。90%的研究组患者和56.7%的对照组患者为男性(P = 0.003)。每组治疗前后的QoL均有显著差异(P<0.05)。然而,治疗后两组之间的QoL评分无统计学差异(P = 0.13)。LVEF也得到了相同的结果(P = 0.18);而纽约心脏协会(NYHA)功能分级在治疗后两组之间存在显著差异(P =
0.017)。根据结果,干细胞治疗HFrEF患者在改善LVEF和QoL方面似乎与传统疗法一样有效,且在提高患者对生活的总体满意度方面比传统治疗更有效。